{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T04:38:05Z","timestamp":1792730285182,"version":"4.5.0"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"DOI":"10.1007\/s40265-026-02398-8","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:59:53Z","timestamp":1792727993000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeted Therapies in Polymyalgia Rheumatica: From Immunopathophysiology to a Redefined Treatment Paradigm"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6384-6458","authenticated-orcid":false,"given":"Dario","family":"Camellino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6956-7860","authenticated-orcid":false,"given":"Marco Amedeo","family":"Cimmino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6970-0983","authenticated-orcid":false,"given":"Elvis","family":"Hysa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,23]]},"reference":[{"key":"2398_CR1","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/s0140-6736(23)01310-7","volume":"402","author":"G Esp\u00edgol-Frigol\u00e9","year":"2023","unstructured":"Esp\u00edgol-Frigol\u00e9 G, Dejaco C, Mackie SL, et al. Polymyalgia rheumatica. Lancet. 2023;402:1459\u201372. https:\/\/doi.org\/10.1016\/s0140-6736(23)01310-7.","journal-title":"Lancet"},{"key":"2398_CR2","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/s40266-019-00705-5","volume":"36","author":"D Camellino","year":"2019","unstructured":"Camellino D, Giusti A, Girasole G, Bianchi G, Dejaco C. Pathogenesis, diagnosis and management of polymyalgia rheumatica. Drugs Aging. 2019;36:1015\u201326. https:\/\/doi.org\/10.1007\/s40266-019-00705-5.","journal-title":"Drugs Aging"},{"key":"2398_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.55563\/jer\/ztobhu","volume":"2","author":"E Hysa","year":"2025","unstructured":"Hysa E, Mantello E, Gotelli E, et al. Environmental factors in polymyalgia rheumatica and giant cell arteritis. J Environm Rheumatol. 2025;2:1\u201310. https:\/\/doi.org\/10.55563\/jer\/ztobhu.","journal-title":"J Environm Rheumatol."},{"key":"2398_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/ard.40.1.1","volume":"40","author":"JG Jones","year":"1981","unstructured":"Jones JG, Hazleman BL. Prognosis and management of polymyalgia rheumatica. Ann Rheum Dis. 1981;40:1\u20135. https:\/\/doi.org\/10.1136\/ard.40.1.1.","journal-title":"Ann Rheum Dis"},{"key":"2398_CR5","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1136\/annrheumdis-2015-207492","volume":"74","author":"C Dejaco","year":"2015","unstructured":"Dejaco C, Singh YP, Perel P, et al. 2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism\/American College of Rheumatology collaborative initiative. Ann Rheum Dis. 2015;74:1799\u2013807. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207492.","journal-title":"Ann Rheum Dis"},{"key":"2398_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s10067-021-05819-z","volume":"41","author":"A Floris","year":"2022","unstructured":"Floris A, Piga M, Chessa E, et al. Long-term glucocorticoid treatment and high relapse rate remain unresolved issues in the real-life management of polymyalgia rheumatica: a systematic literature review and meta-analysis. Clin Rheumatol. 2022;41:19\u201331. https:\/\/doi.org\/10.1007\/s10067-021-05819-z.","journal-title":"Clin Rheumatol"},{"key":"2398_CR7","doi-asserted-by":"publisher","first-page":"i48","DOI":"10.1093\/rheumatology\/keae539","volume":"64","author":"L Iorio","year":"2025","unstructured":"Iorio L, Bond M, Padoan R, Dejaco C. Advances in the treatment of polymyalgia rheumatica. Rheumatology. 2025;64:i48\u201354. https:\/\/doi.org\/10.1093\/rheumatology\/keae539.","journal-title":"Rheumatology"},{"key":"2398_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.152017","volume":"55","author":"AK Hemmig","year":"2022","unstructured":"Hemmig AK, Gozzoli D, Werlen L, et al. Subclinical giant cell arteritis in new onset polymyalgia rheumatica A systematic review and meta-analysis of individual patient data. Semin Arthritis Rheum. 2022;55:152017. https:\/\/doi.org\/10.1016\/j.semarthrit.2022.152017.","journal-title":"Semin Arthritis Rheum"},{"key":"2398_CR9","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1093\/rheumatology\/keaa646","volume":"60","author":"D Camellino","year":"2021","unstructured":"Camellino D, Duftner C, Dejaco C. New insights into the role of imaging in polymyalgia rheumatica. Rheumatology (Oxford). 2021;60:1016\u201333. https:\/\/doi.org\/10.1093\/rheumatology\/keaa646.","journal-title":"Rheumatology (Oxford)"},{"key":"2398_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102995","author":"E Hysa","year":"2021","unstructured":"Hysa E, Gotelli E, Sammor\u00ec S, et al. Immune system activation in polymyalgia rheumatica: which balance between autoinflammation and autoimmunity? A systematic review. Autoimmun Rev. 2021. https:\/\/doi.org\/10.1016\/j.autrev.2021.102995.","journal-title":"Autoimmun Rev"},{"key":"2398_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000694","volume":"4","author":"A Floris","year":"2018","unstructured":"Floris A, Piga M, Cauli A, Salvarani C, Mathieu A. Polymyalgia rheumatica: an autoinflammatory disorder? RMD Open. 2018;4:e000694. https:\/\/doi.org\/10.1136\/rmdopen-2018-000694.","journal-title":"RMD Open"},{"key":"2398_CR12","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41584-021-00652-9","volume":"17","author":"Z Szekanecz","year":"2021","unstructured":"Szekanecz Z, McInnes IB, Schett G, et al. Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases. Nat Rev Rheumatol. 2021;17:585\u201395. https:\/\/doi.org\/10.1038\/s41584-021-00652-9.","journal-title":"Nat Rev Rheumatol"},{"key":"2398_CR13","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1002\/art.1780390719","volume":"39","author":"R Meliconi","year":"1996","unstructured":"Meliconi R, Pulsatelli L, Uguccioni M, et al. Leukocyte infiltration in synovial tissue from the shoulder of patients with polymyalgia rheumatica. Quantitative analysis and influence of corticosteroid treatment. Arthritis Rheum. 1996;39:1199\u2013207. https:\/\/doi.org\/10.1002\/art.1780390719.","journal-title":"Arthritis Rheum"},{"key":"2398_CR14","unstructured":"Matteson EL, Dasgupta B, Schmidt W, et al. A 2-week single-blind, randomized, 3-arm proof of concept study of the effects of secukinumab (anti-IL17 mAb), canakinumab (anti-IL-1 b mAb), or corticosteroids on initial disease activity scores in patients with PMR, followed by an open-label extension to assess safety and effect duration [abstract]. 2014 ACR\/ARHP Annual Meeting."},{"key":"2398_CR15","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1136\/annrheumdis-2011-200413","volume":"71","author":"NT Baerlecken","year":"2012","unstructured":"Baerlecken NT, Linnemann A, Gross WL, et al. Association of ferritin autoantibodies with giant cell arteritis\/polymyalgia rheumatica. Ann Rheum Dis. 2012;71:943\u20137. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200413.","journal-title":"Ann Rheum Dis"},{"key":"2398_CR16","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1136\/ard.43.2.264","volume":"43","author":"MA Sattar","year":"1984","unstructured":"Sattar MA, Cawley MI, Hamblin TJ, Robertson JC. Polymyalgia rheumatica and antimitochondrial antibodies. Ann Rheum Dis. 1984;43:264\u20136. https:\/\/doi.org\/10.1136\/ard.43.2.264.","journal-title":"Ann Rheum Dis"},{"key":"2398_CR17","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1080\/1744666x.2019.1614915","volume":"15","author":"M Cutolo","year":"2019","unstructured":"Cutolo M, Soldano S, Smith V. Pathophysiology of systemic sclerosis: current understanding and new insights. Expert Rev Clin Immunol. 2019;15:753\u201364. https:\/\/doi.org\/10.1080\/1744666x.2019.1614915.","journal-title":"Expert Rev Clin Immunol"},{"key":"2398_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001228","author":"A Catrina","year":"2021","unstructured":"Catrina A, Krishnamurthy A, Rethi B. Current view on the pathogenic role of anti-citrullinated protein antibodies in rheumatoid arthritis. RMD Open. 2021. https:\/\/doi.org\/10.1136\/rmdopen-2020-001228.","journal-title":"RMD Open"},{"key":"2398_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.943574","volume":"13","author":"RD Reitsema","year":"2022","unstructured":"Reitsema RD, Jiemy WF, Wekema L, et al. Contribution of pathogenic T helper 1 and 17 cells to bursitis and tenosynovitis in polymyalgia rheumatica. Front Immunol. 2022;13:943574. https:\/\/doi.org\/10.3389\/fimmu.2022.943574.","journal-title":"Front Immunol"},{"key":"2398_CR20","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1002\/art.38625","volume":"66","author":"KS van der Geest","year":"2014","unstructured":"van der Geest KS, Abdulahad WH, Chalan P, et al. Disturbed B cell homeostasis in newly diagnosed giant cell arteritis and polymyalgia rheumatica. Arthritis Rheumatol. 2014;66:1927\u201338. https:\/\/doi.org\/10.1002\/art.38625.","journal-title":"Arthritis Rheumatol"},{"key":"2398_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.70045","volume":"7","author":"E Hysa","year":"2025","unstructured":"Hysa E, Camellino D, Dejaco C, et al. Soluble co-inhibitory immune checkpoint molecules are increased in patients with polymyalgia rheumatica without significant correlations with clinical status: a case-control study. ACR Open Rheumatol. 2025;7:e70045. https:\/\/doi.org\/10.1002\/acr2.70045.","journal-title":"ACR Open Rheumatol"},{"key":"2398_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103589","author":"E Hysa","year":"2024","unstructured":"Hysa E, Casabella A, Gotelli E, et al. Polymyalgia rheumatica and giant cell arteritis induced by immune checkpoint inhibitors: a systematic literature review highlighting differences from the idiopathic forms. Autoimmun Rev. 2024. https:\/\/doi.org\/10.1016\/j.autrev.2024.103589.","journal-title":"Autoimmun Rev"},{"key":"2398_CR23","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1093\/rheumatology\/keae099","volume":"64","author":"OCB Vermeulen","year":"2025","unstructured":"Vermeulen OCB, Brouwer E, Slart R, et al. Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement. Rheumatology (Oxford). 2025;64:771\u20139. https:\/\/doi.org\/10.1093\/rheumatology\/keae099.","journal-title":"Rheumatology (Oxford)"},{"key":"2398_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-025-01279-w","author":"M Cutolo","year":"2025","unstructured":"Cutolo M, Soldano S, Smith V, Gotelli E, Hysa E. Dynamic macrophage phenotypes in autoimmune and inflammatory rheumatic diseases. Nat Rev Rheumatol. 2025. https:\/\/doi.org\/10.1038\/s41584-025-01279-w.","journal-title":"Nat Rev Rheumatol"},{"key":"2398_CR25","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1136\/ard-2022-222873","volume":"82","author":"WF Jiemy","year":"2023","unstructured":"Jiemy WF, Zhang A, Boots AMH, et al. Expression of interleukin-6 in synovial tissue of patients with polymyalgia rheumatica. Ann Rheum Dis. 2023;82:440\u20132. https:\/\/doi.org\/10.1136\/ard-2022-222873.","journal-title":"Ann Rheum Dis"},{"key":"2398_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.01.004","author":"WF Jiemy","year":"2025","unstructured":"Jiemy WF, Zhang A, Abdulahad WH, et al. GM-CSF drives IL-6 production by macrophages in polymyalgia rheumatica. Ann Rheum Dis. 2025. https:\/\/doi.org\/10.1016\/j.ard.2025.01.004.","journal-title":"Ann Rheum Dis"},{"key":"2398_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-06826-4","volume":"7","author":"Y van Sleen","year":"2017","unstructured":"van Sleen Y, Wang Q, van der Geest KSM, et al. Involvement of monocyte subsets in the immunopathology of giant cell arteritis. Sci Rep. 2017;7:6553. https:\/\/doi.org\/10.1038\/s41598-017-06826-4.","journal-title":"Sci Rep"},{"key":"2398_CR28","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1001\/jama.2022.15459","volume":"328","author":"V Devauchelle-Pensec","year":"2022","unstructured":"Devauchelle-Pensec V, Carvajal-Alegria G, Dernis E, et al. Effect of tocilizumab on disease activity in patients with active polymyalgia rheumatica receiving glucocorticoid therapy: a randomized clinical trial. JAMA. 2022;328:1053\u201362. https:\/\/doi.org\/10.1001\/jama.2022.15459.","journal-title":"JAMA"},{"key":"2398_CR29","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1056\/NEJMoa2303452","volume":"389","author":"RF Spiera","year":"2023","unstructured":"Spiera RF, Unizony S, Warrington KJ, et al. Sarilumab for relapse of polymyalgia rheumatica during glucocorticoid taper. N Engl J Med. 2023;389:1263\u201372. https:\/\/doi.org\/10.1056\/NEJMoa2303452.","journal-title":"N Engl J Med"},{"key":"2398_CR30","doi-asserted-by":"publisher","first-page":"e233","DOI":"10.1016\/s2665-9913(24)00270-4","volume":"7","author":"A Saraux","year":"2025","unstructured":"Saraux A, Carvajal Alegria G, Dernis E, et al. Baricitinib in early polymyalgia rheumatica (BACHELOR): a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Rheumatol. 2025;7:e233\u201342. https:\/\/doi.org\/10.1016\/s2665-9913(24)00270-4.","journal-title":"Lancet Rheumatol"},{"key":"2398_CR31","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1136\/annrheumdis-2021-221865","volume":"81","author":"MC Cid","year":"2022","unstructured":"Cid MC, Unizony SH, Blockmans D, et al. Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2022;81:653\u201361. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221865.","journal-title":"Ann Rheum Dis"},{"key":"2398_CR32","unstructured":"Ramon A, Greigert H, lamarth\u00e9e B, et al. Impact of IL-17A on synovial fibroblast from subacromial bursae [abstract]. Arthritis Rheumatol 2025; 77 (suppl 9):2233-36."},{"key":"2398_CR33","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1136\/annrheumdis-2012-201660","volume":"72","author":"C Dejaco","year":"2013","unstructured":"Dejaco C, Duftner C, Al-Massad J, et al. NKG2D stimulated T-cell autoreactivity in giant cell arteritis and polymyalgia rheumatica. Ann Rheum Dis. 2013;72:1852\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2012-201660.","journal-title":"Ann Rheum Dis"},{"key":"2398_CR34","doi-asserted-by":"publisher","first-page":"e728","DOI":"10.1016\/s2665-9913(23)00246-1","volume":"5","author":"A Saraux","year":"2023","unstructured":"Saraux A, Le Henaff C, Dernis E, et al. Abatacept in early polymyalgia rheumatica (ALORS): a proof-of-concept, randomised, placebo-controlled, parallel-group trial. Lancet Rheumatol. 2023;5:e728\u201335. https:\/\/doi.org\/10.1016\/s2665-9913(23)00246-1.","journal-title":"Lancet Rheumatol"},{"key":"2398_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1201575","volume":"14","author":"RD Reitsema","year":"2023","unstructured":"Reitsema RD, Hesselink BC, Abdulahad WH, et al. Aberrant phenotype of circulating antigen presenting cells in giant cell arteritis and polymyalgia rheumatica. Front Immunol. 2023;14:1201575. https:\/\/doi.org\/10.3389\/fimmu.2023.1201575.","journal-title":"Front Immunol"},{"key":"2398_CR36","doi-asserted-by":"publisher","first-page":"283","DOI":"10.5114\/reum\/170845","volume":"61","author":"E Hysa","year":"2023","unstructured":"Hysa E, Vojinovic T, Gotelli E, et al. The dichotomy of glucocorticosteroid treatment in immune-inflammatory rheumatic diseases: an evidence-based perspective and insights from clinical practice. Reumatologia (Warsz). 2023;61:283\u201393. https:\/\/doi.org\/10.5114\/reum\/170845.","journal-title":"Reumatologia (Warsz)"},{"key":"2398_CR37","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1007\/s10067-026-07965-8","volume":"45","author":"E Hysa","year":"2026","unstructured":"Hysa E, Iandolino N, Balito S, et al. Frailty phenotypes and determinants of glucocorticoid-related adverse events in polymyalgia rheumatica at 12 months: a real-life single-center investigation. Clin Rheumatol. 2026;45:1765\u201377. https:\/\/doi.org\/10.1007\/s10067-026-07965-8.","journal-title":"Clin Rheumatol"},{"key":"2398_CR38","doi-asserted-by":"publisher","first-page":"493","DOI":"10.7326\/0003-4819-141-7-200410050-00005","volume":"141","author":"R Caporali","year":"2004","unstructured":"Caporali R, Cimmino MA, Ferraccioli G, et al. Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2004;141:493\u2013500. https:\/\/doi.org\/10.7326\/0003-4819-141-7-200410050-00005.","journal-title":"Ann Intern Med"},{"key":"2398_CR39","first-page":"624","volume":"23","author":"G Ferraccioli","year":"1996","unstructured":"Ferraccioli G, Salaffi F, De Vita S, Casatta L, Bartoli E. Methotrexate in polymyalgia rheumatica: preliminary results of an open, randomized study. J Rheumatol. 1996;23:624\u20138.","journal-title":"J Rheumatol"},{"key":"2398_CR40","unstructured":"Nazarinia AM, Moghimi J, Toussi J. Efficacy of methotrexate in patients with polymyalgia rheumatica. koomesh. 2013;14(3):e152575."},{"key":"2398_CR41","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1136\/ard.55.4.218","volume":"55","author":"MJ van der Veen","year":"1996","unstructured":"van der Veen MJ, Dinant HJ, van Booma-Frankfort C, van Albada-Kuipers GA, Bijlsma JW. Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis? Ann Rheum Dis. 1996;55:218\u201323. https:\/\/doi.org\/10.1136\/ard.55.4.218.","journal-title":"Ann Rheum Dis"},{"key":"2398_CR42","doi-asserted-by":"publisher","first-page":"366","DOI":"10.5414\/cp203901","volume":"59","author":"GG Song","year":"2021","unstructured":"Song GG, Lee YH. Methotrexate for treating polymyalgia rheumatica: a meta-analysis of randomized controlled trials. Int J Clin Pharmacol Ther. 2021;59:366\u201371. https:\/\/doi.org\/10.5414\/cp203901.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"2398_CR43","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/z9264f","author":"MA Cimmino","year":"2025","unstructured":"Cimmino MA, Camellino D, Clini PV, Cutolo M, Hysa E. Polypharmacy and comorbidities are not higher at diagnosis in patients with polymyalgia rheumatica compared to osteoarthritis. Clin Exp Rheumatol. 2025. https:\/\/doi.org\/10.55563\/clinexprheumatol\/z9264f.","journal-title":"Clin Exp Rheumatol"},{"key":"2398_CR44","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rkae033","volume":"8","author":"JP Vinicki","year":"2024","unstructured":"Vinicki JP, Cusa A, Domingo D, et al. Effectiveness of methotrexate and leflunomide as corticoid-sparing drugs in patients with polymyalgia rheumatica. Rheumatol Adv Pract. 2024;8:rkae033. https:\/\/doi.org\/10.1093\/rap\/rkae033.","journal-title":"Rheumatol Adv Pract"},{"key":"2398_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.11.025","author":"TE Bolhuis","year":"2025","unstructured":"Bolhuis TE, Kooijman N, Marsman DE, et al. Results of a 1-year randomised double-blind placebo-controlled trial with methotrexate 25 mg\/week in recently diagnosed polymyalgia rheumatica. Ann Rheum Dis. 2025. https:\/\/doi.org\/10.1016\/j.ard.2025.11.025.","journal-title":"Ann Rheum Dis"},{"key":"2398_CR46","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s00296-021-04856-w","volume":"41","author":"S Matsushita","year":"2021","unstructured":"Matsushita S, Taito S, Yamamoto N. Does methotrexate have no beneficial effect in reducing flares in the treatment of polymyalgia rheumatica patients? Rheumatol Int. 2021;41:1371\u20132. https:\/\/doi.org\/10.1007\/s00296-021-04856-w.","journal-title":"Rheumatol Int"},{"key":"2398_CR47","doi-asserted-by":"publisher","first-page":"S213","DOI":"10.1097\/rhu.0000000000001414","volume":"26","author":"ML de la Torre","year":"2020","unstructured":"de la Torre ML, Rodr\u00edguez AM, Pisoni CN. Usefulness of methotrexate in the reduction of relapses and recurrences in polymyalgia rheumatica: an observational study. J Clin Rheumatol. 2020;26:S213-s217. https:\/\/doi.org\/10.1097\/rhu.0000000000001414.","journal-title":"J Clin Rheumatol"},{"key":"2398_CR48","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.89107","volume":"17","author":"J Kitai","year":"2025","unstructured":"Kitai J, Miyake H, Sada RM, Tsugihashi Y, Hatta K. Evaluation of the glucocorticoid-sparing effect of adding methotrexate in polymyalgia rheumatica: a single-center retrospective study. Cureus. 2025;17:e89107. https:\/\/doi.org\/10.7759\/cureus.89107.","journal-title":"Cureus"},{"key":"2398_CR49","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1111\/imj.14779","volume":"50","author":"C Ruediger","year":"2020","unstructured":"Ruediger C, Nguyen L, Black R, Proudman S, Hill C. Efficacy of methotrexate in polymyalgia rheumatica in routine rheumatology clinical care. Intern Med J. 2020;50:1067\u201372. https:\/\/doi.org\/10.1111\/imj.14779.","journal-title":"Intern Med J"},{"key":"2398_CR50","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s00296-017-3874-3","volume":"38","author":"K Albrecht","year":"2018","unstructured":"Albrecht K, Huscher D, Buttgereit F, et al. Long-term glucocorticoid treatment in patients with polymyalgia rheumatica, giant cell arteritis, or both diseases: results from a national rheumatology database. Rheumatol Int. 2018;38:569\u201377. https:\/\/doi.org\/10.1007\/s00296-017-3874-3.","journal-title":"Rheumatol Int"},{"key":"2398_CR51","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1613849","volume":"377","author":"JH Stone","year":"2017","unstructured":"Stone JH, Tuckwell K, Dimonaco S, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017;377:317\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1613849.","journal-title":"N Engl J Med"},{"key":"2398_CR52","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.semarthrit.2019.12.005","volume":"50","author":"M Akiyama","year":"2020","unstructured":"Akiyama M, Kaneko Y, Takeuchi T. Tocilizumab in isolated polymyalgia rheumatica: a systematic literature review. Semin Arthritis Rheum. 2020;50:521\u20135. https:\/\/doi.org\/10.1016\/j.semarthrit.2019.12.005.","journal-title":"Semin Arthritis Rheum"},{"key":"2398_CR53","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1093\/rheumatology\/kead471","volume":"63","author":"E Hysa","year":"2024","unstructured":"Hysa E, Bond M, Ehlers L, et al. Evidence on treat to target strategies in polymyalgia rheumatica and giant cell arteritis: a systematic literature review. Rheumatology (Oxford). 2024;63:285\u201397. https:\/\/doi.org\/10.1093\/rheumatology\/kead471.","journal-title":"Rheumatology (Oxford)"},{"key":"2398_CR54","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221126","author":"M Bonelli","year":"2022","unstructured":"Bonelli M, Radner H, Kerschbaumer A, et al. Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2\/3 randomised controlled trial. Ann Rheum Dis. 2022. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221126.","journal-title":"Ann Rheum Dis"},{"key":"2398_CR55","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1002\/art.43221","volume":"77","author":"B Chevet","year":"2025","unstructured":"Chevet B, Souki A, Nowak E, et al. Maintenance of remission after tocilizumab withdrawal in patients with glucocorticoid-dependent polymyalgia rheumatica. Arthritis Rheumatol. 2025;77:1416\u201320. https:\/\/doi.org\/10.1002\/art.43221.","journal-title":"Arthritis Rheumatol"},{"key":"2398_CR56","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185x.70106","volume":"28","author":"M Sharma","year":"2025","unstructured":"Sharma M, Das SK, Mohindra R, Dutta D. Efficacy and safety of tocilizumab in polymyalgia rheumatica: a systematic review and meta-analysis. Int J Rheum Dis. 2025;28:e70106. https:\/\/doi.org\/10.1111\/1756-185x.70106.","journal-title":"Int J Rheum Dis"},{"key":"2398_CR57","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1007\/s00296-018-4086-1","volume":"38","author":"D Camellino","year":"2018","unstructured":"Camellino D, Soldano S, Cutolo M, Cimmino MA. Dissecting the inflammatory response in polymyalgia rheumatica: the relative role of IL-6 and its inhibition. Rheumatol Int. 2018;38:1699\u2013704. https:\/\/doi.org\/10.1007\/s00296-018-4086-1.","journal-title":"Rheumatol Int"},{"issue":"11","key":"2398_CR58","doi-asserted-by":"publisher","first-page":"e758","DOI":"10.1016\/S2665-9913(21)00245-9","volume":"3","author":"DE Marsman","year":"2021","unstructured":"Marsman DE, den Broeder N, van den Hoogen FHJ, den Broeder AA, Van der Maas A. Efficacy of rituximab in patients with polymyalgia rheumatica: a double-blind, randomised, placebo-controlled, proof-of-concept trial. Lancet Rheumatol. 2021;3(11):e758\u201366. (10.1016\/S2665-9913%2821%2900245-9).","journal-title":"Lancet Rheumatol"},{"key":"2398_CR59","doi-asserted-by":"publisher","first-page":"e208","DOI":"10.1016\/s2665-9913(23)00032-2","volume":"5","author":"TE Bolhuis","year":"2023","unstructured":"Bolhuis TE, Marsman DE, den Broeder AA, den Broeder N, van der Maas A. 1-year results of treatment with rituximab in polymyalgia rheumatica: an extension study of a randomised double-blind placebo-controlled trial. Lancet Rheumatol. 2023;5:e208\u201314. https:\/\/doi.org\/10.1016\/s2665-9913(23)00032-2.","journal-title":"Lancet Rheumatol"},{"key":"2398_CR60","doi-asserted-by":"publisher","unstructured":"Kooijman N, Bovens P, den Broeder N, et al OP0123 Rituximab as a glucocorticoid-sparing therapy in newly diagnosed polymyalgia rheumatica: a randomized controlled trial (REDUCE PMR 1). Annals of the Rheumatic Diseases 2026, EULAR 2026 abstract archive volume 85, supplement 1, page s105, https:\/\/doi.org\/10.1136\/annrheumdis-2026-eular.B.1217","DOI":"10.1136\/annrheumdis-2026-eular.B.1217"},{"key":"2398_CR61","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2602567","author":"JH Stone","year":"2026","unstructured":"Stone JH, Buttgereit F, Saraux A, et al. Phase 3 trial of secukinumab in polymyalgia rheumatica. N Engl J Med. 2026. https:\/\/doi.org\/10.1056\/NEJMoa2602567.","journal-title":"N Engl J Med"},{"issue":"7","key":"2398_CR62","doi-asserted-by":"publisher","first-page":"EVIDoa2600112","DOI":"10.1056\/EVIDoa2600112","volume":"5","author":"JH Stone","year":"2026","unstructured":"Stone JH, Venhoff N, Buttgereit F, et al. Secukinumab for giant cell arteritis. NEJM Evid. 2026;5(7):EVIDoa2600112. https:\/\/doi.org\/10.1056\/EVIDoa2600112.","journal-title":"NEJM Evid."},{"key":"2398_CR63","doi-asserted-by":"publisher","first-page":"e341","DOI":"10.1016\/S2665-9913(23)00101-7","volume":"5","author":"N Venhoff","year":"2023","unstructured":"Venhoff N, Schmidt WA, Bergner R, et al. Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Rheumatol. 2023;5:e341\u201350. https:\/\/doi.org\/10.1016\/S2665-9913(23)00101-7.","journal-title":"Lancet Rheumatol"},{"key":"2398_CR64","doi-asserted-by":"publisher","DOI":"10.4081\/reumatismo.2024.1796","author":"D Camellino","year":"2025","unstructured":"Camellino D, Dejaco C, Martini F, Cosso R, Bianchi G. Baricitinib in polymyalgia rheumatica and giant cell arteritis: report of six cases. Reumatismo. 2025. https:\/\/doi.org\/10.4081\/reumatismo.2024.1796.","journal-title":"Reumatismo"},{"key":"2398_CR65","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-024-03314-9","volume":"26","author":"J Loricera","year":"2024","unstructured":"Loricera J, Tofade T, Prieto-Pe\u00f1a D, et al. Effectiveness of janus kinase inhibitors in relapsing giant cell arteritis in real-world clinical practice and review of the literature. Arthritis Res Ther. 2024;26:116. https:\/\/doi.org\/10.1186\/s13075-024-03314-9.","journal-title":"Arthritis Res Ther"},{"key":"2398_CR66","unstructured":"Lechner-Radner H, Anderle K, Bond M et al. LB0005 Baricitinib for remission induction and glucocorticoid sparing in new-onset polymyalgia rheumatica (JAK-SPARE): a phase iii randomized controlled trial. Annals of the Rheumatic Diseases 2026, EULAR 2026 abstract archive volume 85, supplement 1, page s308, annrheumdis-2026-eular.LBA_B.61"},{"key":"2398_CR67","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004249","volume":"20","author":"X Ma","year":"2023","unstructured":"Ma X, Yang F, Wu J, et al. Efficacy and safety of tofacitinib in patients with polymyalgia rheumatica (EAST PMR): an open-label randomized controlled trial. PLoS Med. 2023;20:e1004249. https:\/\/doi.org\/10.1371\/journal.pmed.1004249.","journal-title":"PLoS Med"},{"key":"2398_CR68","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1136\/ard-2022-223562","volume":"82","author":"L Zhang","year":"2023","unstructured":"Zhang L, Li J, Yin H, et al. Efficacy and safety of tofacitinib in patients with polymyalgia rheumatica: a phase 2 study. Ann Rheum Dis. 2023;82:722\u20134. https:\/\/doi.org\/10.1136\/ard-2022-223562.","journal-title":"Ann Rheum Dis"},{"key":"2398_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1\u201310. https:\/\/doi.org\/10.1016\/0197-2456(89)90015-9.","journal-title":"Control Clin Trials"},{"issue":"Suppl 1","key":"2398_CR70","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.ard.2025.06.143","volume":"84","author":"Y He","year":"2025","unstructured":"He Y, Yang F, Wu J, et al. POS0784: efficacy and safety of induction and tapering therapy with tofacitinib and glucocorticoid in patients with polymyalgia rheumatica (ITTG PMR). Ann Rheum Dis. 2025;84(Suppl 1):943. https:\/\/doi.org\/10.1016\/j.ard.2025.06.143.","journal-title":"Ann Rheum Dis"},{"key":"2398_CR71","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1056\/NEJMoa2413449","volume":"392","author":"D Blockmans","year":"2025","unstructured":"Blockmans D, Penn SK, Setty AR, et al. A phase 3 trial of upadacitinib for giant-cell arteritis. N Engl J Med. 2025;392:2013\u201324. https:\/\/doi.org\/10.1056\/NEJMoa2413449.","journal-title":"N Engl J Med"},{"key":"2398_CR72","unstructured":"Merkel P, Setty A, Blanco-Alonso R, et al. Efficacy of Upadacitinib in Patients with Giant Cell Arteritis: Subgroup Analysis of the SELECT-GCA Phase 3 Trial [abstract]. Arthritis Rheumatol. 2024;76 (suppl 9):3457-60."},{"key":"2398_CR73","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386:316\u201326. https:\/\/doi.org\/10.1056\/NEJMoa2109927.","journal-title":"N Engl J Med"},{"key":"2398_CR74","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1136\/ard-2023-224670","volume":"83","author":"R Aymon","year":"2024","unstructured":"Aymon R, Mongin D, Bergstra SA, et al. Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the \u201cJAK-pot\u201d study). Ann Rheum Dis. 2024;83:421\u20138. https:\/\/doi.org\/10.1136\/ard-2023-224670.","journal-title":"Ann Rheum Dis"},{"key":"2398_CR75","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s40264-025-01535-8","volume":"48","author":"R Di Napoli","year":"2025","unstructured":"Di Napoli R, Richez C, Scavone C, et al. Major adverse cardiovascular events related to JAK inhibitors: a disproportionality analysis using the WHO global individual case safety database. Drug Saf. 2025;48:943\u201352. https:\/\/doi.org\/10.1007\/s40264-025-01535-8.","journal-title":"Drug Saf"},{"key":"2398_CR76","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003432","volume":"17","author":"M Pujades-Rodriguez","year":"2020","unstructured":"Pujades-Rodriguez M, Morgan AW, Cubbon RM, Wu J. Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases: a population-based cohort study. PLoS Med. 2020;17:e1003432. https:\/\/doi.org\/10.1371\/journal.pmed.1003432.","journal-title":"PLoS Med"},{"key":"2398_CR77","doi-asserted-by":"publisher","first-page":"552","DOI":"10.3899\/jrheum.110851","volume":"39","author":"M Mazzantini","year":"2012","unstructured":"Mazzantini M, Torre C, Miccoli M, et al. Adverse events during longterm low-dose glucocorticoid treatment of polymyalgia rheumatica: a retrospective study. J Rheumatol. 2012;39:552\u20137. https:\/\/doi.org\/10.3899\/jrheum.110851.","journal-title":"J Rheumatol"},{"key":"2398_CR78","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.tips.2025.06.005","volume":"46","author":"F Buttgereit","year":"2025","unstructured":"Buttgereit F, Elling C, Jakob F. Design and development of glucocorticoid receptor modulators. Trends Pharmacol Sci. 2025;46:771\u201391. https:\/\/doi.org\/10.1016\/j.tips.2025.06.005.","journal-title":"Trends Pharmacol Sci"},{"key":"2398_CR79","doi-asserted-by":"publisher","first-page":"12544","DOI":"10.1021\/acs.jmedchem.3c01174","volume":"66","author":"AD Hobson","year":"2023","unstructured":"Hobson AD, Xu J, Welch DS, et al. Discovery of ABBV-154, an anti-TNF glucocorticoid receptor modulator immunology antibody-drug conjugate (iADC). J Med Chem. 2023;66:12544\u201358. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c01174.","journal-title":"J Med Chem"},{"key":"2398_CR80","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1002\/art.43129","volume":"77","author":"RF Spiera","year":"2025","unstructured":"Spiera RF, Devauchelle-Pensec V, Owen CE, et al. Efficacy, safety, pharmacokinetics, and immunogenicity of ABBV-154 in adults with glucocorticoid-dependent polymyalgia rheumatica: a phase 2, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2025;77:1041\u201351. https:\/\/doi.org\/10.1002\/art.43129.","journal-title":"Arthritis Rheumatol"},{"key":"2398_CR81","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.ard.2025.10.015","volume":"85","author":"F Buttgereit","year":"2026","unstructured":"Buttgereit F, Everding A, Andreica I, et al. Effects of clofutriben, a selective 11\u03b2-hydroxysteroid dehydrogenase type 1 inhibitor, on the efficacy and toxicity of prednisolone in patients with polymyalgia rheumatica: a single-blind controlled trial with sequential cohorts. Ann Rheum Dis. 2026;85:921\u201331. https:\/\/doi.org\/10.1016\/j.ard.2025.10.015.","journal-title":"Ann Rheum Dis"},{"key":"2398_CR82","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/rheumatology\/keae428","volume":"64","author":"TE Bolhuis","year":"2025","unstructured":"Bolhuis TE, Bosch P, Falzon L, et al. Definitions of and instruments for disease activity, remission and relapse in polymyalgia rheumatica: a systematic literature review. Rheumatology (Oxford). 2025;64:455\u201369. https:\/\/doi.org\/10.1093\/rheumatology\/keae428.","journal-title":"Rheumatology (Oxford)"},{"key":"2398_CR83","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1136\/ard.2003.011379","volume":"63","author":"BF Leeb","year":"2004","unstructured":"Leeb BF, Bird HA. A disease activity score for polymyalgia rheumatica. Ann Rheum Dis. 2004;63:1279\u201383. https:\/\/doi.org\/10.1136\/ard.2003.011379.","journal-title":"Ann Rheum Dis"},{"key":"2398_CR84","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.rdc.2019.07.005","volume":"45","author":"D Camellino","year":"2019","unstructured":"Camellino D, Dejaco C, Buttgereit F, Matteson EL. Treat to target: a valid concept for management of polymyalgia rheumatica and giant cell arteritis? Rheum Dis Clin N Am. 2019;45:549\u201367. https:\/\/doi.org\/10.1016\/j.rdc.2019.07.005.","journal-title":"Rheum Dis Clin N Am"},{"key":"2398_CR85","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/ard-2022-223429","volume":"83","author":"C Dejaco","year":"2024","unstructured":"Dejaco C, Kerschbaumer A, Aletaha D, et al. Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica. Ann Rheum Dis. 2024;83:48\u201357. https:\/\/doi.org\/10.1136\/ard-2022-223429.","journal-title":"Ann Rheum Dis"},{"key":"2398_CR86","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1007\/s00393-025-01667-3","volume":"84","author":"F Buttgereit","year":"2025","unstructured":"Buttgereit F, Boyadzhieva Z, Reisch M, et al. S2e guidelines on the treatment of polymyalgia rheumatica: update 2024: evidence-based guidelines of the German Society for Rheumatology and Clinical Immunology (DGRh), the Austrian Society for Rheumatology and Rehabilitation (\u00d6GR) and the Swiss Society for Rheumatology (SGR) and the participating medical scientific specialist societies and other organizations. Z Rheumatol. 2025;84:494\u2013505. https:\/\/doi.org\/10.1007\/s00393-025-01667-3.","journal-title":"Z Rheumatol"},{"key":"2398_CR87","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ard.2025.05.085","volume":"84","author":"N Venhoff","year":"2025","unstructured":"Venhoff N, Schmidt W, Bergner R, et al. OP0062 Secukinumab in patients with giant cell arteritis with polymyalgia rheumatica symptoms: a post hoc analysis of the phase 2 TitAIN study. Ann Rheum Dis. 2025;84:54\u20135. https:\/\/doi.org\/10.1016\/j.ard.2025.05.085.","journal-title":"Ann Rheum Dis"},{"key":"2398_CR88","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1001\/jamainternmed.2016.6008","volume":"176","author":"TJ Hwang","year":"2016","unstructured":"Hwang TJ, Carpenter D, Lauffenburger JC, et al. Failure of investigational drugs in late-stage clinical development and publication of trial results. JAMA Intern Med. 2016;176:1826\u201333. https:\/\/doi.org\/10.1001\/jamainternmed.2016.6008.","journal-title":"JAMA Intern Med"},{"key":"2398_CR89","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1056\/NEJMra1909094","volume":"385","author":"G Schett","year":"2021","unstructured":"Schett G, McInnes IB, Neurath MF. Reframing immune-mediated inflammatory diseases through signature cytokine hubs. N Engl J Med. 2021;385:628\u201339. https:\/\/doi.org\/10.1056\/NEJMra1909094.","journal-title":"N Engl J Med"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02398-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02398-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02398-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:59:55Z","timestamp":1792727995000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02398-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,23]]},"references-count":89,"alternative-id":["2398"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02398-8","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,23]]},"assertion":[{"value":"3 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DC has received research funding related to clinical trials in the last three years, paid to the health trust (not directly), from AbbVie, Galapagos, and Pfizer. DC has served as a paid consultant, instructor, or speaker for Abiogen, Alfasigma, AstraZeneca, Boehringer Ingelheim, GSK, IBSA, Johnson & Johnson, and Neopharmed Gentili. DC has also received reimbursement for travel to attend congresses and symposia from AbbVie, GSK, Novartis, and UCB. None of these activities is related to the present manuscript. MAC declares no conflict of interest related to this manuscript. EH has received research support from AbbVie, unrelated to the writing of this manuscript.\n                      Ethics Approval\n                      Not Applicable.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Availability of Data and Materials","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Artificial intelligence (ChatGPT, version GPT-5; OpenAI) was used for language refinement and typographical correctionsduring the final stage of manuscript revision. Artificial intelligence was not employed for conceptualisation, data extraction,analysis, or visualisation. The authors critically reviewed and revised all outputs and take full responsibility for the accuracyand integrity of the content. All concepts, interpretations, and conclusions are the sole intellectual property of the authors.","order":6,"name":"Ethics","label":"AI use","group":{"name":"EthicsHeading","label":"Declarations"}}]}}